Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene...

Area of Science:

• Immunology
• Pharmacology
• Molecular Biology

Background:

• Laquinimod (LAQ) is an immunomodulatory drug effective for relapsing-remitting multiple sclerosis (RRMS).
• The precise molecular mechanisms and pathways targeted by LAQ remain incompletely understood.

Purpose of the Study:

• To investigate the in-vitro molecular effects of Laquinimod (LAQ) on peripheral blood mononuclear cells (PBMCs).
• To elucidate the molecular pathways influenced by LAQ in both healthy individuals and RRMS patients.

Main Methods:

• Gene expression microarrays were employed to analyze PBMCs from healthy subjects and RRMS patients.
• Analysis focused on identifying changes in gene expression profiles following LAQ treatment.
• PBMC subpopulations (CD14+, CD4+, CD8+) were analyzed for specific cellular responses.

Main Results:

• LAQ significantly suppressed genes associated with antigen presentation and inflammatory pathways.
• The observed effects were primarily mediated through the Nuclear Factor kappa B (NFkB) pathway.
• LAQ induced a Th2 immune response in CD14+ and CD4+ cells.
• LAQ suppressed the proliferation of CD8+ T-cells.

Conclusions:

• Laquinimod modulates immune responses by suppressing key inflammatory pathways, notably the NFkB pathway.
• LAQ exhibits distinct effects on immune cell subsets, including Th2 activation and CD8+ T-cell suppression.
• These findings provide novel insights into the molecular mechanisms underlying LAQ's therapeutic efficacy in RRMS.